News
NTRB
3.060
+0.99%
0.030
Nutriband Secures New Three-Year $5M Credit Facility
TipRanks · 6d ago
Nutriband amends $5 million credit line facility at 7% interest
PUBT · 6d ago
NUTRIBAND - CREDIT LINE DOES NOT PERMIT CONVERSION OF OUTSTANDING AMOUNTS INTO COMMON STOCK - SEC FILING
Reuters · 6d ago
Weekly Report: what happened at NTRB last week (0615-0619)?
Weekly Report · 6d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 06/18 21:06
Weekly Report: what happened at NTRB last week (0608-0612)?
Weekly Report · 06/15 10:40
Nutriband Q1 EPS $(0.10) Up From $(0.12) YoY, Sales $433.399K Down From $667.432K YoY
Benzinga · 06/11 21:16
Nutriband FY27 Q1 net loss narrows to $1.24 million; revenue falls to $433,399
PUBT · 06/11 20:21
Weekly Report: what happened at NTRB last week (0601-0605)?
Weekly Report · 06/08 10:35
Weekly Report: what happened at NTRB last week (0525-0529)?
Weekly Report · 06/01 10:41
Weekly Report: what happened at NTRB last week (0518-0522)?
Weekly Report · 05/25 10:45
Weekly Report: what happened at NTRB last week (0511-0515)?
Weekly Report · 05/18 10:44
Nutriband attends ECRM conference to showcase Active Intelligence wellness products
PUBT · 05/15 11:02
Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference
Barchart · 05/15 06:00
Weekly Report: what happened at NTRB last week (0504-0508)?
Weekly Report · 05/11 10:41
Weekly Report: what happened at NTRB last week (0427-0501)?
Weekly Report · 05/04 10:37
Nutriband FY26 net loss narrows to $8.23 million; revenue slips to $2.04 million
PUBT · 04/29 21:39
Weekly Report: what happened at NTRB last week (0420-0424)?
Weekly Report · 04/27 10:41
Nutriband CEO Sheridan discusses fentanyl crisis, AVERSA technology on Jack Neel Podcast
PUBT · 04/22 11:05
Weekly Report: what happened at NTRB last week (0413-0417)?
Weekly Report · 04/20 10:36
More
Webull provides a variety of real-time NTRB stock news. You can receive the latest news about Nutriband Inc through multiple platforms. This information may help you make smarter investment decisions.
About NTRB
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.